Halozyme Therapeutics | HALO - صافي الدخل





صافي الدخل تغيير تاريخ
Acadia Pharmaceuticals USD 273.57M 201.79M 2025-12
Agios Pharmaceuticals USD -108.04M 4.61M 2025-12
Alnylam Pharmaceuticals USD 186.42M 64.66M 2025-12
Amarin USD -1.22M 6.51M 2025-12
Amgen USD 1.33B 1.88B 2025-12
Baxter International USD -1.13B 1.08B 2025-12
Cara Therapeutics USD -4.91M 2.77M 2025-03
Cytokinetics USD -183.03M 123.15M 2025-12
DBV Technologies USD -33.16M 8.71M 2025-09
Eli Lilly USD 6.64B 1.05B 2025-12
Esperion Therapeutics USD 61.83M 93.16M 2025-12
Halozyme Therapeutics USD -141.59M 316.82M 2025-12
Ionis Pharmaceuticals USD -229M 100.39M 2025-12
MannKind USD -15.95M 23.93M 2025-12
Minerva Neurosciences USD 1.44M 21.07M 2024-12
Nektar Therapeutics USD -37.06M 15.31M 2024-09
Pfizer USD -1.65B 5.19B 2025-12
Rigel Pharmaceuticals USD 12.42M 13.45M 2024-09
United Therapeutics USD 364.3M 25.6M 2025-12
Vanda Pharmaceuticals USD -18.9M 13.58M 2024-12